Cross-sectional study of second-line therapy administration after platinum-based chemotherapy for patients with advanced NSCLC.

Cross-sectional study of second-line therapy administration after platinum-based chemotherapy for patients with advanced NSCLC. - Second-line chemotherapy administration for patients with advanced NSCLC, who completed platinum-based "Hyojun" (standard) doublet, In the follow-up period, and at recurrence.(SAPPHIRE)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000006393

Enrollment

750

Registered

2011-09-22

Start date

2010-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced lung cancer

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients who were diagnosed as advanced or recurrent NSCLC before this study. 2)Consecutive patients in each institution who had started first-line platinum chemotherapy in combination with third generation agent after April 1, 2010.

Exclusion criteria

Exclusion criteria: 1)Recurrent NSCLC patients who had undergone adjuvant platinum based chemotherapy. 2)Active double cancer.

Design outcomes

Primary

Measure	Time frame
Proportion of the patients administered the second-line chemotherapy	—

Secondary

Measure	Time frame
1)Proportion of the patients who had PD for first-line chemotherapy 2)Proportion of the patients who were administered second-line chemotherapy 3)Proportion of the patients who were administered third-line chemotherapy after the second-line chemotherapy 4)Proportion of the patients who were administered second-line chemotherapy after having PD for first-line chemotherapy. 5)Proportion of the patients who were administered second-line chemotherapy after taking maintenance chemotherapy.	—

Measure

Time frame

1)Proportion of the patients who had PD for first-line chemotherapy 2)Proportion of the patients who were administered second-line chemotherapy 3)Proportion of the patients who were administered third-line chemotherapy after the second-line chemotherapy 4)Proportion of the patients who were administered second-line chemotherapy after having PD for first-line chemotherapy. 5)Proportion of the patients who were administered second-line chemotherapy after taking maintenance chemotherapy.

—

Countries

Japan

Contacts

Public ContactAkira Yamao

Public Health Research Foundation Comprehensive Support Project for Clinical Research

info@csp.or.jp03-5287-2633

Outcome results